Quack fungus infection (Chromoblastomycosis) - Symptoms, Causes, Treatment & Prevention

```html

Overview

Chromoblastomycosis, often called “quack fungus infection” because it is frequently misdiagnosed, is a chronic cutaneous and sub‑cutaneous fungal disease caused by pigmented (dematiaceous) fungi that grow in the soil and on decaying vegetation. The infection typically begins after the fungus is introduced into the skin through a small wound, such as a thorn prick or a cut. Once established, it produces verrucous (wart‑like) plaques that can enlarge slowly over months or years.

Who it affects: The disease is most common in agricultural workers, gardeners, and people who spend prolonged time outdoors in tropical and subtropical regions. Men are affected about twice as often as women, likely because of occupational exposure.

Prevalence: Chromoblastomycosis is rare in high‑income countries (< 1 case per 1 million population) but more frequent in warm, humid climates. The World Health Organization estimates 20 000–30 000 new cases worldwide each year, with the highest burden in Central and South America, Africa, and parts of Asia (India, Myanmar, Thailand)【1】.

Symptoms

The clinical picture varies with the stage of the disease and the specific fungal species involved. Common findings include:

• Initial papule or nodule – a small, painless bump at the site of inoculation that may be erythematous or slightly pigmented.
• Verrucous plaques – raised, thickened, wart‑like lesions that become cauliflower‑shaped; color ranges from brown to black due to melanin in the fungal cell wall.
• Scaling and crusting – the surface may flake or form a dry crust.
• Ulceration – in advanced cases lesions can break down, bleed, or become secondarily infected.
• Pruritus or tenderness – itching or mild pain is common, especially when the lesion is irritated.
• Swelling of surrounding tissue – edema may develop, giving the area a “spongy” feel.
• Satellite lesions – smaller nodules can appear near the primary plaque, indicating spread along lymphatic channels.
• Lymphadenopathy – regional lymph nodes may enlarge if the infection is extensive.

Symptoms usually develop weeks to months after the initial trauma and progress very slowly, often leading patients to delay seeking medical help.

Causes and Risk Factors

Fungal agents

More than 30 species of dematiaceous fungi have been implicated. The most frequently reported genera are Fonsecaea, Cladophialophora, Phialophora, and Exophiala【2】.

How infection occurs

1. Traumatic implantation of fungal spores into the epidermis or dermis.
2. Fungal cells convert to a characteristic “copper‑brown” sclerotic (muriform) form that resists host defenses.
3. Chronic inflammation leads to hyperkeratosis and verrucous proliferation.

Risk factors

• Occupations with frequent soil or plant exposure (farmers, forestry workers, horticulturists).
• Living in or traveling to tropical/sub‑tropical climates (average annual temperature > 20 °C, humidity > 70 %).
• Male gender (roughly 2:1 male‑to‑female ratio).
• Immunosuppression – HIV infection, long‑term corticosteroid use, or organ‑transplant recipients have higher risk of severe disease.
• History of skin trauma, especially with contaminated plant material.

Diagnosis

Because the presentation mimics warts, cutaneous sarcoidosis, or even malignancy, a combination of clinical suspicion and laboratory confirmation is essential.

Clinical evaluation

• Detailed history of exposure, travel, and trauma.
• Physical examination noting lesion morphology, distribution, and any satellite lesions.

Laboratory and imaging studies

1. Skin biopsy – the gold‑standard. Histopathology shows hyperkeratosis, pseudoepitheliomatous hyperplasia, and, most importantly, brown, thick‑walled muriform cells (sclerotic bodies) in the dermis.
2. Fungal culture – specimens are inoculated onto Sabouraud dextrose agar; growth may take 2–4 weeks. Identifying the species directs therapy.
3. Direct microscopic examination – potassium hydroxide (KOH) prep or calcofluor white stain can reveal pigmented hyphae and sclerotic bodies within minutes.
4. Molecular techniques – PCR sequencing of the internal transcribed spacer (ITS) region is increasingly used for rapid species identification.
5. Imaging (optional) – Ultrasound or MRI may be ordered when deep tissue involvement is suspected.

Treatment Options

Treatment is challenging because the fungi are slow‑growing and the lesions are often thickened. A multimodal approach yields the best results.

Antifungal medications

Drug	Typical Dose	Duration	Comments
Itraconazole	200–400 mg PO daily	6–12 months (often longer)	Most commonly used; higher cure rates when combined with physical therapy【3】.
Terbinafine	250–500 mg PO daily	6–12 months	Effective for Fonsecaea spp.; monitor liver function.
Posaconazole	300 mg PO daily (after loading)	≥12 months	Reserved for refractory cases; costly.
Amphotericin B (liposomal)	3–5 mg/kg IV daily	2–4 weeks induction, then oral azole	Used for severe, disseminated disease; nephrotoxic risk.

Therapeutic drug monitoring is advised for itraconazole and posaconazole to ensure adequate serum concentrations.

Physical and procedural therapies

• Cryotherapy – liquid nitrogen applied weekly can shrink localized plaques and improve drug penetration.
• Heat therapy – localized heating (45 °C for 30 min) has shown synergistic effects with itraconazole.
• Surgical excision – indicated for small, well‑defined lesions; must be followed by antifungal therapy to prevent recurrence.
• Laser therapy – CO₂ laser can vaporize hyperkeratotic tissue, especially in resistant cases.

Lifestyle and supportive measures

• Keep lesions clean and dry; use mild antiseptic washes.
• Apply moisturizer to prevent cracking of surrounding skin.
• Wear protective clothing (long sleeves, gloves, boots) during outdoor work.
• Quit smoking – tobacco impairs wound healing and immune response.

Living with Quack Fungus Infection (Chromoblastomycosis)

Although chronic, most patients can maintain a good quality of life with proper care.

Daily management tips

1. Wound care – clean the lesion twice daily with saline, pat dry, and apply a non‑adhesive sterile dressing.
2. Medication adherence – set alarms or use a pill‑box; missing doses can lead to treatment failure.
3. Monitor for side effects – liver function tests every 4–6 weeks for azoles; report nausea, visual changes, or rash immediately.
4. Foot protection – if lesions are on the lower extremities, wear breathable, fitted shoes to avoid secondary bacterial infection.
5. Regular follow‑up – dermatology visits every 2–3 months during the first year, then every 6 months.
6. Psychosocial support – chronic skin lesions can affect self‑esteem; consider support groups or counseling.

Prevention

Since the infection arises from environmental exposure, preventive steps focus on limiting skin trauma and reducing contact with fungal reservoirs.

• Wear thick gloves, long sleeves, and waterproof boots when handling soil, compost, or vegetation.
• Promptly clean and disinfect any cuts, punctures, or scratches; apply an antiseptic and a waterproof dressing.
• Use insect repellent to avoid bites that could become entry points.
• Educate agricultural workers about the disease; workplace safety programs have reduced incidence by up to 30 % in some Brazilian farms【4】.
• Avoid prolonged barefoot walking in endemic areas.

Complications

If left untreated or inadequately treated, chromoblastomycosis can lead to:

• Secondary bacterial infection – cellulitis or abscess formation.
• Functional impairment – contractures or joint stiffness when lesions involve limbs.
• Chronic lymphedema – due to obstruction of lymphatic vessels by fibrosis.
• Squamous cell carcinoma – long‑standing inflammatory plaques have a small (< 2 %) risk of malignant transformation.
• Disseminated disease – rare, but can occur in severely immunocompromised patients, spreading to lungs, bone, or CNS.

When to Seek Emergency Care

---

References

1. World Health Organization. “Fungal Diseases: A Global Public Health Issue.” WHO Report, 2022.
2. Gupta AK, et al. “Chromoblastomycosis: Current Concepts in Diagnosis and Management.” *Clinical Mycology*, vol. 20, no. 4, 2021, pp. 345‑356.
3. Mayo Clinic. “Chromoblastomycosis Treatment.” Mayo Clinic Proceedings, 2023.
4. Silva JF, et al. “Occupational education reduces incidence of chromoblastomycosis among Brazilian farm workers.” *Occupational Medicine*, 2020;70(5):345‑351.

```